Follicular Lymphoma

Oncology
27
Pipeline Programs
16
Companies
30
Clinical Trials
5 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
2
14
0
4
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
545%
Small Molecule
436%
Cell Therapy
218%
+ 15 programs with unclassified modality

On Market (2)

Approved therapies currently available

U
IDELALISIBApproved
idelalisib
Unknown Company
oral2026
GS
ZYDELIGApproved
idelalisib
Gilead Sciences
Kinase Inhibitor [EPC]oral2014

Competitive Landscape

16 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
6 programs
2
1
2
1
1
IdelalisibPhase 3Small Molecule1 trial
Axicabtagene ciloleucelPhase 2Cell Therapy1 trial
IdelalisibPhase 2Small Molecule1 trial
90Y-epratuzumab tetraxetanPhase 1/21 trial
GS-9901Phase 1
+1 more programs
Active Trials
NCT02258555Terminated7Est. Aug 2015
NCT01147393Terminated4Est. Jul 2015
NCT03105336Completed159Est. Dec 2024
+2 more trials
Roche
RocheSTAVANGER NORWAY, Norway
3 programs
1
1
Rituximab IVPhase 31 trial
Obinutuzumab 25 MG/1 ML Intravenous SolutionPhase 21 trial
RituximabN/AMonoclonal Antibody1 trial
Active Trials
NCT02316613Completed260Est. Apr 2013
NCT04962126Active Not Recruiting15Est. Jul 2025
NCT02303119Completed221Est. Jun 2021
Celltrion
CelltrionKorea - Incheon
1 program
1
CT-P10Phase 31 trial
Active Trials
NCT02260804Completed258Est. Sep 2019
CT
1 program
1
TQB2825 InjectionPhase 31 trial
Active Trials
NCT07187960Not Yet RecruitingEst. Feb 2029
Novartis
NovartisBASEL, Switzerland
2 programs
1
1
tisagenlecleucelPhase 2Cell Therapy1 trial
HCD122Phase 11 trial
Active Trials
NCT01275209Completed1Est. May 2012
NCT03568461Completed98Est. May 2025
TG Therapeutics
TG TherapeuticsNEW YORK, NY
2 programs
2
TGR-1202Phase 21 trial
UblituximabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03178201TerminatedEst. Jun 2020
NCT03828448Terminated34Est. May 2022
Ipsen
IpsenChina - Tianjin
2 programs
2
TazemetostatPhase 2Small Molecule1 trial
TazverikPhase 21 trial
Active Trials
NCT04762160Terminated5Est. Mar 2022
NCT06068881Withdrawn0Est. Apr 2029
Takeda
TakedaTOKYO, Japan
1 program
1
IXAZOMIBPhase 21 trial
Active Trials
NCT01939899Completed29Est. Mar 2017
ADC Therapeutics
ADC TherapeuticsNJ - New Providence
1 program
1
Loncastuximab tesirinePhase 21 trial
Active Trials
NCT04998669RecruitingEst. Aug 2030
Bristol Myers Squibb
1 program
1
ObinutuzumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT06108232Recruiting36Est. Dec 2027
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
OdronextamabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT07128641Recruiting35Est. Jan 2028
BeOne Medicines
BeOne MedicinesCA - San Carlos
1 program
1
ZanubrutinibPhase 2Small Molecule1 trial
Active Trials
NCT06350318RecruitingEst. Mar 2029
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
1
fludarabinePhase 25 trials
Active Trials
NCT05521087Withdrawn0Est. Jan 2030
NCT07149857Recruiting60Est. Apr 2029
NCT05347485Completed86Est. Dec 2023
+2 more trials
Genentech
GenentechCA - Oceanside
1 program
1
ObinutuzumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT01691898Completed231Est. Feb 2019
M&
Merck & Co.RAHWAY, NJ
1 program
1
MK-8808Phase 11 trial
Active Trials
NCT01370694Terminated7Est. Dec 2014
Sound Biologics
Sound BiologicsWA - Bothell
1 program
1
PSB202Phase 11 trial
Active Trials
NCT05003141Unknown110Est. Jan 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Chia Tai TianQing Pharmaceutical GroupTQB2825 Injection
Johnson & Johnsonfludarabine
Gilead SciencesIdelalisib
CelltrionCT-P10
RocheRituximab IV
Johnson & Johnsonfludarabine
RegeneronOdronextamab
IpsenTazverik
BeOne MedicinesZanubrutinib
Bristol Myers SquibbObinutuzumab
Johnson & Johnsonfludarabine
ADC TherapeuticsLoncastuximab tesirine
RocheObinutuzumab 25 MG/1 ML Intravenous Solution
IpsenTazemetostat
TG TherapeuticsUblituximab

Showing 15 of 30 trials with date data

Clinical Trials (30)

Total enrollment: 2,950 patients across 30 trials

NCT07187960Chia Tai TianQing Pharmaceutical GroupTQB2825 Injection

Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma

Start: Nov 2025Est. completion: Feb 2029
Phase 3Not Yet Recruiting
NCT02950051Johnson & Johnsonfludarabine

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Start: Dec 2016Est. completion: Feb 2024926 patients
Phase 3Completed
NCT02536300Gilead SciencesIdelalisib

Dose Optimization Study of Idelalisib in Follicular Lymphoma

Start: Jan 2016Est. completion: Sep 202296 patients
Phase 3Terminated
NCT02260804CelltrionCT-P10

To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma

Start: Nov 2015Est. completion: Sep 2019258 patients
Phase 3Completed
NCT02303119RocheRituximab IV

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)

Start: Feb 2015Est. completion: Jun 2021221 patients
Phase 3Completed
NCT07149857Johnson & Johnsonfludarabine

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

Start: Oct 2025Est. completion: Apr 202960 patients
Phase 2Recruiting
NCT07128641RegeneronOdronextamab

Odronextamab in Low Tumor Volume Advanced FL

Start: Sep 2025Est. completion: Jan 202835 patients
Phase 2Recruiting
NCT06068881IpsenTazverik

A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation

Start: Sep 2025Est. completion: Apr 20290
Phase 2Withdrawn
NCT06350318BeOne MedicinesZanubrutinib

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Start: Apr 2024Est. completion: Mar 2029
Phase 2Recruiting
NCT06108232Bristol Myers SquibbObinutuzumab

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Start: Mar 2024Est. completion: Dec 202736 patients
Phase 2Recruiting
NCT05347485Johnson & Johnsonfludarabine

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

Start: May 2022Est. completion: Dec 202386 patients
Phase 2Completed
NCT04998669ADC TherapeuticsLoncastuximab tesirine

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Start: Feb 2022Est. completion: Aug 2030
Phase 2Recruiting
NCT04962126RocheObinutuzumab 25 MG/1 ML Intravenous Solution

Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy

Start: Aug 2021Est. completion: Jul 202515 patients
Phase 2Active Not Recruiting
NCT04762160IpsenTazemetostat

SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

Start: Dec 2020Est. completion: Mar 20225 patients
Phase 2Terminated
NCT03828448TG TherapeuticsUblituximab

Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma

Start: Jul 2019Est. completion: May 202234 patients
Phase 2Terminated
NCT03568461Novartistisagenlecleucel

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

Start: Nov 2018Est. completion: May 202598 patients
Phase 2Completed
NCT03178201TG TherapeuticsTGR-1202

TGR1202 in Relapsed and Refractory Follicular Lymphoma

Start: Aug 2017Est. completion: Jun 2020
Phase 2Terminated
NCT03105336Gilead SciencesAxicabtagene ciloleucel

A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Start: Jun 2017Est. completion: Dec 2024159 patients
Phase 2Completed
NCT02666898Johnson & Johnsonfludarabine

Phase II Trial GA101 Inbrutinib B CLL

Start: Oct 2015Est. completion: Sep 2023135 patients
Phase 2Completed
NCT01939899TakedaIXAZOMIB

Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma

Start: Oct 2013Est. completion: Mar 201729 patients
Phase 2Completed
NCT01282424Gilead SciencesIdelalisib

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas

Start: Mar 2011Est. completion: May 2018125 patients
Phase 2Completed
NCT00850499Johnson & Johnsonfludarabine

Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab

Start: Sep 2009Est. completion: Oct 201112 patients
Phase 2Terminated
NCT01691898GenentechObinutuzumab

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Start: Sep 2012Est. completion: Feb 2019231 patients
Phase 1/2Completed
NCT01147393Gilead Sciences90Y-epratuzumab tetraxetan

Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma

Start: Oct 2010Est. completion: Jul 20154 patients
Phase 1/2Terminated
NCT05521087Johnson & Johnsonfludarabine

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

Start: Dec 2025Est. completion: Jan 20300
Phase 1Withdrawn
NCT05003141Sound BiologicsPSB202

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Start: Nov 2021Est. completion: Jan 2024110 patients
Phase 1Unknown
NCT02258555Gilead SciencesGS-9901

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma

Start: Jan 2015Est. completion: Aug 20157 patients
Phase 1Terminated
NCT01370694Merck & Co.MK-8808

Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)

Start: Aug 2011Est. completion: Dec 20147 patients
Phase 1Terminated
NCT01275209NovartisHCD122

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma

Start: Feb 2011Est. completion: May 20121 patients
Phase 1Completed
NCT02316613RocheRituximab

Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)

Start: Feb 2007Est. completion: Apr 2013260 patients
N/ACompleted

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
5h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
7h ago

Executive Medical Director, Oncology Early Development

AbbVie
Florham Park, NJ
8h ago

Executive Medical Director, Oncology Early Development

AbbVie
South San Francisco, CA
8h ago

Executive Medical Director, Oncology Early Development

AbbVie
North Chicago, IL
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
5 actively recruiting trials targeting 2,950 patients
16 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)